Please wait while the formulary information is being retrieved.
Drug overview for FROTEK (ketoprofen):
Generic name: ketoprofen
Drug class: Non-Steroidal Anti-Inflammatory (NSAID) and Salicylates
Therapeutic class: Dermatological
Ketoprofen is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) that also exhibits analgesic and antipyretic activity.
Ketoprofen is used for anti-inflammatory and analgesic effects in the symptomatic treatment of acute and chronic rheumatoid arthritis and osteoarthritis. Ketoprofen also is used to relieve mild to moderate pain and for the management of primary dysmenorrhea. Extended-release capsules of ketoprofen are not recommended for the management of acute pain.
The potential benefits and risks of ketoprofen therapy as well as alternative therapies should be considered prior to initiating ketoprofen therapy. The lowest possible effective dosage and shortest duration of therapy consistent with treatment goals of the patient should be employed.
Generic name: ketoprofen
Drug class: Non-Steroidal Anti-Inflammatory (NSAID) and Salicylates
Therapeutic class: Dermatological
Ketoprofen is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) that also exhibits analgesic and antipyretic activity.
Ketoprofen is used for anti-inflammatory and analgesic effects in the symptomatic treatment of acute and chronic rheumatoid arthritis and osteoarthritis. Ketoprofen also is used to relieve mild to moderate pain and for the management of primary dysmenorrhea. Extended-release capsules of ketoprofen are not recommended for the management of acute pain.
The potential benefits and risks of ketoprofen therapy as well as alternative therapies should be considered prior to initiating ketoprofen therapy. The lowest possible effective dosage and shortest duration of therapy consistent with treatment goals of the patient should be employed.
DRUG IMAGES
No Image Available
The following indications for FROTEK (ketoprofen) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for FROTEK (ketoprofen):
The lowest possible effective dosage and shortest duration of therapy consistent with treatment goals of the patient should be employed. Dosage of ketoprofen must be carefully adjusted according to individual requirements and response, using the lowest possible effective dosage.
Since ketoprofen and its metabolites are excreted mainly by the kidneys, the manufacturers recommend that the maximum daily dosage of the drug be reduced in patients with renal impairment. The maximum dosage of ketoprofen given as conventional or extended-release capsules in patients with mild renal impairment is 150 mg daily, while the maximum dosage in patients with more severe renal impairment (i.e., those with creatinine clearances less than 25 mL/minute per 1.73 m2 or end-stage renal disease) is 100 mg daily (given as conventional or extended-release capsules). Use of ketoprofen in patients with severe renal impairment is not recommended; however, if ketoprofen is used in these patients, close monitoring is recommended.
Patients with impaired hepatic function and serum albumin concentrations less than 3.5 g/dL should receive an initial ketoprofen dosage of 100 mg daily as conventional or extended-release capsules. The manufacturers also recommend that ketoprofen therapy be initiated at low dosages in patients with both hypoalbuminemia and renal impairment, since these patients may be at greater risk of developing adverse effects secondary to increased plasma concentrations of free ketoprofen.
If the drug is used in patients with both hypoalbuminemia and impaired renal or hepatic function, the patients should be closely monitored.
When ketoprofen is used for relief of mild to moderate pain or dysmenorrhea, the manufacturers recommend that therapy be initiated with relatively small dosages in patients with renal or hepatic disease.
Since ketoprofen and its metabolites are excreted mainly by the kidneys, the manufacturers recommend that the maximum daily dosage of the drug be reduced in patients with renal impairment. The maximum dosage of ketoprofen given as conventional or extended-release capsules in patients with mild renal impairment is 150 mg daily, while the maximum dosage in patients with more severe renal impairment (i.e., those with creatinine clearances less than 25 mL/minute per 1.73 m2 or end-stage renal disease) is 100 mg daily (given as conventional or extended-release capsules). Use of ketoprofen in patients with severe renal impairment is not recommended; however, if ketoprofen is used in these patients, close monitoring is recommended.
Patients with impaired hepatic function and serum albumin concentrations less than 3.5 g/dL should receive an initial ketoprofen dosage of 100 mg daily as conventional or extended-release capsules. The manufacturers also recommend that ketoprofen therapy be initiated at low dosages in patients with both hypoalbuminemia and renal impairment, since these patients may be at greater risk of developing adverse effects secondary to increased plasma concentrations of free ketoprofen.
If the drug is used in patients with both hypoalbuminemia and impaired renal or hepatic function, the patients should be closely monitored.
When ketoprofen is used for relief of mild to moderate pain or dysmenorrhea, the manufacturers recommend that therapy be initiated with relatively small dosages in patients with renal or hepatic disease.
The potential benefits and risks of ketoprofen therapy as well as alternative therapies should be considered prior to initiating ketoprofen therapy. Ketoprofen is administered orally. Adverse GI effects may be minimized by administering the drug with meals, milk, or an antacid.
Extended-release capsules of ketoprofen are not recommended for the management of acute pain. In addition, concomitant use of ketoprofen conventional and extended-release capsules is not recommended.
Extended-release capsules of ketoprofen are not recommended for the management of acute pain. In addition, concomitant use of ketoprofen conventional and extended-release capsules is not recommended.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for FROTEK (ketoprofen):
There are 0 contraindications.
There are 3 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Aminolevulinic Acid/Selected Photosensitizers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Aminolevulinic acid, anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides are all known photosensitizers.(1) CLINICAL EFFECTS: Concurrent use of aminolevulinic acid in patients taking anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides may increase the risk of phototoxicity.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer states that aminolevulinic acid should be avoided in patients receiving photosensitizers including anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides for 24 hours before and after administration of aminolevulinic acid.(1) DISCUSSION: Because of the risk of increased photosensitivity, the US manufacturer states that aminolevulinic acid should be avoided in patients receiving photosensitizers including anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides for 24 hours before and after administration of aminolevulinic acid.(1) |
AMINOLEVULINIC ACID HCL, GLEOLAN |
| Porfimer/Selected Photosensitizers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Porfimer causes photosensitivity due to residual drug which is present in all parts of the skin. Anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides are other known photosensitizers.(1) CLINICAL EFFECTS: Concurrent use of porfimer in patients taking anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides may increase the risk of phototoxicity.(1) PREDISPOSING FACTORS: Patients with any hepatic impairment and patients with severe renal impairment have reduced drug elimination and may remain photosensitive for 90 days or longer.(1) PATIENT MANAGEMENT: The US manufacturer of porfimer states that concurrent use of porfimer with photosensitizers including anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides should be avoided.(1) Since the photosensitive effect of porfimer may persist for at least 30 days (and for 90 days in some patients), it would be prudent to avoid other photosensitizing agents for at least 30 days after administration of porfimer. DISCUSSION: All patients who have received porfimer become photosensitive. It is unknown what the risk of photosensitivity reactions is when porfimer is used concurrently with other photosensitizing agents. When porfimer was used in clinical trials, photosensitivity reactions occurred in about 20% of cancer patients and in 69% of high-grade dysplasia in Barretts esophagus patients. Most of the reactions were mild to moderate erythema, but they also included swelling, pruritus, burning sensation, feeling hot, or blisters. The majority of reactions occurred within 90 days of porfimer administration.(1) |
PHOTOFRIN |
| Methoxsalen/Selected Photosensitizers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Methoxsalen causes photosensitivity due to residual drug which is present in all parts of the skin from photopheresis. Anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides are other known photosensitizers.(1) CLINICAL EFFECTS: Concurrent use of methoxsalen in patients taking anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides may increase the risk of phototoxicity.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of methoxsalen states that concurrent use of methoxsalen with anthralin, coal tar and derivatives, fluoroquinolones, griseofulvin, organic staining dyes (such as methylene blue, rose bengal, or toluidine blue), phenothiazines, selected NSAIDs (such as diclofenac, ketoprofen, nabumetone, naproxen, piroxicam, and tiaprofenic acid), St. John's wort, sulfonamides, sulfonylureas, tetracyclines, and thiazides should be avoided.(1) DISCUSSION: All patients who have received methoxsalen become photosensitive. It is unknown what the risk of photosensitivity reactions is when methoxsalen is used concurrently with other photosensitizing agents.(1) |
METHOXSALEN, UVADEX |
There are 0 moderate interactions.
The following contraindication information is available for FROTEK (ketoprofen):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 6 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Aspirin exacerbated respiratory disease |
| Cerebrovascular accident |
| History of roux-en-Y gastric bypass |
| Post-operative from CABG surgery |
| Pregnancy |
| Renal transplant |
There are 16 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Acute myocardial infarction |
| Chronic heart failure |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Gastrointestinal hemorrhage |
| Gastrointestinal ulcer |
| History of kidney donation |
| Increased risk of bleeding |
| Increased risk of bleeding due to coagulation disorder |
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
| Nephrectomy |
| Peptic ulcer |
| Severe hepatic disease |
| Systemic mastocytosis |
| Thrombotic disorder |
| Tobacco smoker |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hypertension |
| Hypoalbuminemia |
The following adverse reaction information is available for FROTEK (ketoprofen):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 4 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Erythema Skin rash |
| Rare/Very Rare |
|---|
|
Bullous dermatitis Pruritus of skin |
There are 3 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Skin irritation |
| Rare/Very Rare |
|---|
|
Eczema Skin photosensitivity |
The following precautions are available for FROTEK (ketoprofen):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Use of NSAIAs during pregnancy at about 30 weeks of gestation or later can cause premature closure of the fetal ductus arteriosus, and use at about 20 weeks of gestation or later has been associated with fetal renal dysfunction resulting in oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, use of NSAIAs should be avoided in pregnant women at about 30 weeks of gestation or later; if NSAIA therapy is necessary between about 20 and 30 weeks of gestation, the lowest effective dosage and shortest possible duration of treatment should be used. Monitoring of amniotic fluid volume via ultrasound examination should be considered if the duration of NSAIA treatment exceeds 48 hours; if oligohydramnios occurs, the drug should be discontinued and follow-up instituted according to clinical practice.
Pregnant women should be advised to avoid use of NSAIAs beginning at 20 weeks' gestation unless otherwise advised by a clinician; they should be informed that NSAIAs should be avoided beginning at 30 weeks' gestation because of the risk of premature closure of the fetal ductus arteriosus and that monitoring for oligohydramnios may be necessary if NSAIA therapy is required for longer than 48 hours' duration between about 20 and 30 weeks of gestation. Known effects of NSAIAs on the human fetus during the third trimester of pregnancy include prenatal constriction of the ductus arteriosus, tricuspid incompetence, and pulmonary hypertension; nonclosure of the ductus arteriosus during the postnatal period (which may be resistant to medical management); and myocardial degenerative changes, platelet dysfunction with resultant bleeding, intracranial bleeding, renal dysfunction or renal failure, renal injury or dysgenesis potentially resulting in prolonged or permanent renal failure, oligohydramnios, GI bleeding or perforation, and increased risk of necrotizing enterocolitis. Fetal renal dysfunction resulting in oligohydramnios and, in some cases, neonatal renal impairment has been observed, on average, following days to weeks of maternal NSAIA use, although oligohydramnios has been observed infrequently as early as 48 hours after initiation of NSAIA therapy.
Oligohydramnios is often, but not always, reversible (generally within 3-6 days) following discontinuance of NSAIA therapy. Complications of prolonged oligohydramnios may include limb contracture and delayed lung maturation. A limited number of case reports have described maternal NSAIA use and neonatal renal dysfunction, in some cases irreversible, without oligohydramnios.
Some cases of neonatal renal dysfunction have required treatment with invasive procedures such as exchange transfusion or dialysis. Deaths associated with neonatal renal failure have been reported. Methodologic limitations of these postmarketing studies and case reports include lack of a control group; limited information regarding dosage, duration, and timing of drug exposure; and concomitant use of other drugs.
These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal NSAIA use. Available data on neonatal outcomes generally involved preterm infants, and the extent to which certain reported risks can be generalized to full-term infants is uncertain. Animal data indicate that prostaglandins have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization.
In animal studies, inhibitors of prostaglandin synthesis, such as ketoprofen, were associated with increased pre- and post-implantation losses. Prostaglandins also have an important role in fetal kidney development. In animal studies, inhibitors of prostaglandin synthesis impaired kidney development at clinically relevant doses.
In animal reproduction studies in mice and rats, no teratogenic or embryotoxic effects were observed at ketoprofen dosages up to approximately 0.2 times the maximum recommended human dosage of 185 mg/m2 daily. In rabbits, maternally toxic dosages were associated with embryotoxicity but not with teratogenicity.
The effects of ketoprofen on labor and delivery in humans currently are not known, but the drug has delayed parturition in rats when administered in doses of 6 mg/kg (about 0.2 times the maximum daily recommended human dosage based on body surface area) before the onset of labor.
Pregnant women should be advised to avoid use of NSAIAs beginning at 20 weeks' gestation unless otherwise advised by a clinician; they should be informed that NSAIAs should be avoided beginning at 30 weeks' gestation because of the risk of premature closure of the fetal ductus arteriosus and that monitoring for oligohydramnios may be necessary if NSAIA therapy is required for longer than 48 hours' duration between about 20 and 30 weeks of gestation. Known effects of NSAIAs on the human fetus during the third trimester of pregnancy include prenatal constriction of the ductus arteriosus, tricuspid incompetence, and pulmonary hypertension; nonclosure of the ductus arteriosus during the postnatal period (which may be resistant to medical management); and myocardial degenerative changes, platelet dysfunction with resultant bleeding, intracranial bleeding, renal dysfunction or renal failure, renal injury or dysgenesis potentially resulting in prolonged or permanent renal failure, oligohydramnios, GI bleeding or perforation, and increased risk of necrotizing enterocolitis. Fetal renal dysfunction resulting in oligohydramnios and, in some cases, neonatal renal impairment has been observed, on average, following days to weeks of maternal NSAIA use, although oligohydramnios has been observed infrequently as early as 48 hours after initiation of NSAIA therapy.
Oligohydramnios is often, but not always, reversible (generally within 3-6 days) following discontinuance of NSAIA therapy. Complications of prolonged oligohydramnios may include limb contracture and delayed lung maturation. A limited number of case reports have described maternal NSAIA use and neonatal renal dysfunction, in some cases irreversible, without oligohydramnios.
Some cases of neonatal renal dysfunction have required treatment with invasive procedures such as exchange transfusion or dialysis. Deaths associated with neonatal renal failure have been reported. Methodologic limitations of these postmarketing studies and case reports include lack of a control group; limited information regarding dosage, duration, and timing of drug exposure; and concomitant use of other drugs.
These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal NSAIA use. Available data on neonatal outcomes generally involved preterm infants, and the extent to which certain reported risks can be generalized to full-term infants is uncertain. Animal data indicate that prostaglandins have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization.
In animal studies, inhibitors of prostaglandin synthesis, such as ketoprofen, were associated with increased pre- and post-implantation losses. Prostaglandins also have an important role in fetal kidney development. In animal studies, inhibitors of prostaglandin synthesis impaired kidney development at clinically relevant doses.
In animal reproduction studies in mice and rats, no teratogenic or embryotoxic effects were observed at ketoprofen dosages up to approximately 0.2 times the maximum recommended human dosage of 185 mg/m2 daily. In rabbits, maternally toxic dosages were associated with embryotoxicity but not with teratogenicity.
The effects of ketoprofen on labor and delivery in humans currently are not known, but the drug has delayed parturition in rats when administered in doses of 6 mg/kg (about 0.2 times the maximum daily recommended human dosage based on body surface area) before the onset of labor.
It is not known whether ketoprofen is distributed into human milk; 4-5% of circulating plasma concentrations of the drug are distributed into the milk of lactating dogs. In rats, perinatal development was not adversely affected in nursing offspring whose mothers received ketoprofen doses of 9 mg/kg (approximately 0.3 times the maximum daily recommended human dosage based on body surface area). The manufacturers recommend that ketoprofen not be used in nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for FROTEK (ketoprofen):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for FROTEK (ketoprofen)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool